Epigenetic Characteristics in Primary and Recurrent Glioblastoma-Influence on the Clinical Course
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Epigenetic markers in glioblastoma (GBM) are often unstable during disease progression. This temporal instability in markers like MGMT methylation and miRNA expression can impact their prognostic value in glioblastoma.
Area Of Science
- Neuro-oncology
- Molecular biology
- Cancer epigenetics
Background
- Glioblastoma (GBM) prognosis is increasingly linked to epigenetic tumor characteristics.
- The stability of these epigenetic markers throughout disease progression is crucial for understanding their prognostic reliability.
Purpose Of The Study
- To investigate the temporal stability of key epigenetic markers (MGMT, p15, p16 methylation; miRNA-21, -24, -26a, -181d expression) in glioblastoma.
- To determine if changes in these markers during disease progression influence their prognostic value.
Main Methods
- Analysis of primary and relapse tumor specimens from 44 glioblastoma patients.
- Evaluation of methylation status for MGMT, p15, and p16.
- Assessment of miRNA-21, -24, -26a, and -181d expression levels.
- Correlation of epigenetic marker stability with clinical data and validation using TCGA dataset.
Main Results
- Significant instability observed across all examined epigenetic markers.
- MGMT, p15, and p16 methylation changed in 30-37.5% of patients.
- MiRNA expression varied, with some patients showing stable expression; decreased miRNA-21 in recurrence correlated with longer survival.
- TCGA dataset validated these findings.
Conclusions
- Epigenetic characteristics of glioblastoma are dynamic and can change during disease progression.
- The temporal instability of molecular markers may affect their utility as reliable prognostic indicators in glioblastoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.